menu ☰
menu ˟

FDA unable to grant approval for baricitinib’s new drug application

14 Apr 2017
In a complete response letter issued to Eli Lilly and Incyte today, the FDA did not approve the new drug application for baricitinib in its current form. Baricitinib is an investigational once-daily oral Janus kinase inhibitor for the treatment of mo...

Click here to view the full article which appeared in Rheumatology

Please note

The news articles accessible on the Health Well website have been compiled from various sources that are not controlled by the Institute of Public Health in Ireland (IPH). IPH is therefore not responsible for the content of external websites and the inclusion of a link to an external website from the Health Well should not be understood to be an endorsement of that website.